644981-89-5

Basic information

• Product Name: N-BOC-4-(P-FLUOROPHENYL)-4-PIPERIDINECARBOXYLIC ACID
• Synonyms: N-BOC-4-(P-FLUOROPHENYL)-4-PIPERIDINECARBOXYLIC ACID;1-(TERT-BUTOXYCARBONYL)-4-(4-FLUOROPHENYL)PIPERIDINE-4-CARBOXYLIC ACID;1-BOC-4-(4-FLUOROPHENYL)-4-PIPERIDINEDICARBOXYLIC ACID;Boc-4-(4-fluorophenyl)-piperidine-4-carboxylic acid;1-Boc-4-(4-fluorophenyl)-4-piperidinecarboxylic acid
• CAS NO: 644981-89-5
• Molecular Formula: C17H22FNO4
• Molecular Weight: 323.36
• Mol File: 644981-89-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-BOC-4-(P-FLUOROPHENYL)-4-PIPERIDINECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-4-(P-FLUOROPHENYL)-4-PIPERIDINECARBOXYLIC ACID(644981-89-5)
• EPA Substance Registry System: N-BOC-4-(P-FLUOROPHENYL)-4-PIPERIDINECARBOXYLIC ACID(644981-89-5)

Safety Data

• Hazard Codes: T,N
• Statements: 25-50/53
• Safety Statements: 45-61
• Hazardous Substances Data: 644981-89-5(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white powder

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 1429661-32-4 C₁₉H₂₆FNO₄ 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 256951-79-8 4-(4-fluorophenyl)-tert-butoxycarbonylpiperidine-4-carbonitrile 

Relevant articles and documents

Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant

A series of AKT inhibitors possessing a piperidin-4-yl side chain was designed and synthesized. Some of them showed high AKT1 inhibitory activity and potent anti-proliferative effect on PC-3 prostate cancer cells in the preliminary screening. Further studies revealed the most potent compound, 10h, as a pan-AKT inhibitor. Compound 10h was able to inhibit the cellular phosphorylation of AKT effectively and induce apoptosis of PC-3 cells. It also showed high metabolic stability in human liver microsomes. Preclinical characterization of 10h, a promising lead AKT inhibitor, as a potential anti-prostate cancer therapeutic needs to be further investigated.

Substituted Heterocyclic Ethers and Their Use in CNS Disorders

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.